Scholarlink

<p>Patients with type 2 diabetes mellitus and obesity have a higher risk of cardiovascular disease and major adverse cardiovascular events. It is important that medication options for these disease states are either cardioprotective or cardioneutral so that the health of the patient is not worsened. Medications in the glucagon-like peptide-1 receptor agonists class decrease cardiovascular risk in those at high or increased risk of cardiovascular events. This review presents and discusses the current clinical and scientific evidence pertaining to tirzepatide, a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor co-agonist.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of Tirzepatide on Cardiovascular Outcomes

  • 期刊论文

  • 发表日期：

    2025年10月1日

查看全文
  • Jessica Huston,
  • Dontia Orey,
  • Andrew Ashchi,
  • Andrea Ashchi Lachapelle,
  • Ariana Genovese,
  • Jenna Jackson,
  • Ramsey Ashchi,
  • Towfeeq Ashchi,
  • Majdi Ashchi,
  • David Sutton,
  • Wasim Deeb,
  • Rebecca F. Goldfaden

摘要

Patients with type 2 diabetes mellitus and obesity have a higher risk of cardiovascular disease and major adverse cardiovascular events. It is important that medication options for these disease states are either cardioprotective or cardioneutral so that the health of the patient is not worsened. Medications in the glucagon-like peptide-1 receptor agonists class decrease cardiovascular risk in those at high or increased risk of cardiovascular events. This review presents and discusses the current clinical and scientific evidence pertaining to tirzepatide, a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor co-agonist.